➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Dow
Mallinckrodt
Boehringer Ingelheim
Express Scripts
Harvard Business School

Last Updated: January 15, 2021

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022370

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

NDA 022370 describes CONZIP, which is a drug marketed by Cipher Pharms Inc and is included in one NDA. It is available from five suppliers. There is one patent protecting this drug. Additional details are available on the CONZIP profile page.

The generic ingredient in CONZIP is tramadol hydrochloride. There are thirty-six drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the tramadol hydrochloride profile page.
Summary for 022370
Tradename:CONZIP
Applicant:Cipher Pharms Inc
Ingredient:tramadol hydrochloride
Patents:1
Formulation / Manufacturing:see details
Pharmacology for NDA: 022370
Mechanism of ActionFull Opioid Agonists
Medical Subject Heading (MeSH) Categories for 022370
Suppliers and Packaging for NDA: 022370
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CONZIP tramadol hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022370 NDA AUTHORIZED GENERIC Trigen Laboratories, LLC 13811-689 13811-689-30 30 CAPSULE in 1 BOTTLE, PLASTIC (13811-689-30)
CONZIP tramadol hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022370 NDA AUTHORIZED GENERIC Trigen Laboratories, LLC 13811-690 13811-690-30 30 CAPSULE in 1 BOTTLE, PLASTIC (13811-690-30)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength100MG
Approval Date:May 7, 2010TE:RLD:Yes
Patent:  Start TrialPatent Expiration:Apr 11, 2022Product Flag?YSubstance Flag?Delist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength200MG
Approval Date:May 7, 2010TE:RLD:Yes
Patent:  Start TrialPatent Expiration:Apr 11, 2022Product Flag?YSubstance Flag?Delist Request?

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength300MG
Approval Date:May 7, 2010TE:RLD:Yes
Patent:  Start TrialPatent Expiration:Apr 11, 2022Product Flag?YSubstance Flag?Delist Request?

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Harvard Business School
AstraZeneca
McKinsey
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.